The Enterprise Value as of December 2024 (TTM) for Outlook Therapeutics, Inc. (OTLK) is 34.76M

According to Outlook Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 34.76M. This represents a change of -73.01% compared to the average of 128.79M of the last 4 quarters.

Outlook Therapeutics, Inc. (OTLK) Historical Enterprise Value (quarterly & annually)

How has OTLK Enterprise Value performed in the past?

The mean historical Enterprise Value of Outlook Therapeutics, Inc. over the last ten years is 117.18M. The current 34.76M Enterprise Value has changed 2.87% with respect to the historical average. Over the past ten years (40 quarters), OTLK's Enterprise Value was at its highest in in the June 2023 quarter at 448.01M. The Enterprise Value was at its lowest in in the March 2015 quarter at 0.

Outlook Therapeutics, Inc. (OTLK) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Outlook Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Outlook Therapeutics, Inc. (OTLK) Average Enterprise Value

How has OTLK Enterprise Value performed in the past?

The current Enterprise Value of Outlook Therapeutics, Inc. (OTLK) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Outlook Therapeutics, Inc. (OTLK) Enterprise Value vs. Peers

How is OTLK’s Enterprise Value compared to its peers?

Outlook Therapeutics, Inc.’s Enterprise Value is less than Checkpoint Therapeutics, Inc. (175.79M), greater than Mustang Bio, Inc. (5.64M), less than Reviva Pharmaceuticals Holdings, Inc. (40.86M), less than Fortress Biotech, Inc. (60.16M), less than Kodiak Sciences Inc. (330.77M), greater than Ocuphire Pharma, Inc. (-9671816.00), less than Protalix BioTherapeutics, Inc. (107.87M), less than EyePoint Pharmaceuticals, Inc. (426.67M), less than SELLAS Life Sciences Group, Inc. (42.04M), greater than Eyenovia, Inc. (15.33M), less than Cidara Therapeutics, Inc. (40.18M), less than Fortress Biotech, Inc. (60.16M), less than Selecta Biosciences, Inc. (69.24M), less than X4 Pharmaceuticals, Inc. (85.05M), less than Inozyme Pharma, Inc. (214.30M), less than Terns Pharmaceuticals, Inc. (228.91M), less than Day One Biopharmaceuticals, Inc. (869.67M), greater than HOOKIPA Pharma Inc. (-37421860.00), less than Heron Therapeutics, Inc. (392.82M), greater than Galera Therapeutics, Inc. (-6768842.00),

Build a custom stock screener for Outlook Therapeutics, Inc. (OTLK) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Outlook Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Outlook Therapeutics, Inc. (OTLK) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Outlook Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.